title: The Effect of Docetaxel-Loaded Micro-Bubbles Combined with Low-Frequency Ultrasound in H22 Hepatocellular Carcinoma-Bearing Mice.
abstract: A novel lipid micro-bubble (MB) loaded with docetaxel (DOC-MB) was investigated in a previous study. However, its anti-tumor effects and mechanism of action in combination with low-frequency ultrasound (LFUS) in vivo are still unclear. DOC-MBs containing 5.0 mg of DOC were prepared by lyophilization with modification via ultrasonic emulsification. Then, the effects of DOC-MBs combined with LFUS on tumor growth, proliferating cell nuclear antigen (PCNA) expression and cell apoptosis, as well as local DOC delivery, were investigated in H22 hepatocellular carcinoma (HCC)-bearing mice. Compared with the previously prepared DOC-MBs (1.6 mg of DOC loaded), the encapsulation efficiency (81.2% ± 3.89%) and concentration ([7.94 ± 0.04] × 10(9) bubbles/mL) of the DOC-MBs containing 5.0 mg of DOC were higher, but the bubble size (1.368 ± 0.004 μm) was smaller. After treatment with the DOC-MBs and LFUS, the H22 HCC growth inhibition rate was significantly increased, PCNA expression in tumor tissue was significantly inhibited and local release of DOC was induced. In conclusion, new DOC-MBs containing 5.0 mg of DOC were successfully prepared with a high encapsulation efficiency and superior bubble size and concentration, and their combination with LFUS significantly enhanced the anti-tumor effect of DOC in H22 HCC-bearing mice by inhibiting tumor cell proliferation and increasing local drug delivery.
authors.affiliation: Department of Pathology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China. Electronic address: rst@mail.xjtu.edu.cn.
authors.forename: Shu-Ting
authors.initials: ST
authors.lastname: Ren
authors.affiliation: Department of Pathology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China; Second Division of In Vitro Diagnostic Reagents, National Institute of Food and Drug Control, Beijing, China.
authors.forename: Shu
authors.initials: S
authors.lastname: Shen
authors.affiliation: Department of Pathology, Xi'an Medical University, Xi'an, China.
authors.forename: Xin-Ying
authors.initials: XY
authors.lastname: He
authors.affiliation: Department of Pathology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.
authors.forename: Yi-Ran
authors.initials: YR
authors.lastname: Liao
authors.affiliation: Department of Pathology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.
authors.forename: Peng-Fei
authors.initials: PF
authors.lastname: Sun
authors.affiliation: Department of Pathology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China; Therapeutic Vaccines Engineering Center of Shaanxi Province, Xi'an Jiaotong University Health Science Center, Xi'an, China.
authors.forename: Bing
authors.initials: B
authors.lastname: Wang
authors.affiliation: Department of Pathology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.
authors.forename: Wen-Bao
authors.initials: WB
authors.lastname: Zhao
authors.affiliation: Department of Pathology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.
authors.forename: Shui-Ping
authors.initials: SP
authors.lastname: Han
authors.affiliation: Department of Pathology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China; Institute of Cancer Research, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.
authors.forename: Yi-Li
authors.initials: YL
authors.lastname: Wang
authors.affiliation: Department of Pathology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.
authors.forename: Tian
authors.initials: T
authors.lastname: Tian
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000138:chemical synthesis; D000077143:Docetaxel; D005260:Female; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D045423:Microbubbles / Q000627:therapeutic use*; D013010:Sonication / Q000379:methods*; D043823:Taxoids / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D043823:Taxoids; D000077143:Docetaxel
keywords: Docetaxel; H22 hepatocellular carcinoma; Micro-bubble; Target drug delivery; Ultrasound